Dermatology Treatments Including Omliclo for Chronic Spontaneous Urticaria
Celltrion announced on September 10 that it will participate in the 2025 European Academy of Dermatology and Venereology (EADV), which will be held in Paris, France, from September 17 to 20 (local time). At the event, the company will showcase the competitiveness of its dermatology treatments, including Omliclo (development code: CT-P39, active ingredient: omalizumab), a treatment for chronic spontaneous urticaria (CSU).
Celebrating its 34th year, EADV is one of the world’s most prestigious dermatology conferences, attended by more than 16,000 medical professionals in dermatology and venereology each year. The event serves as a platform for sharing the latest clinical research and trends in treatment development.
On the second day of the conference, September 18, Celltrion will host a symposium titled “Utilization and Understanding of Biosimilars in Chronic Spontaneous Urticaria.” Key opinion leaders (KOLs) from Europe will participate as speakers, presenting 40 weeks of clinical data from Omliclo’s global Phase 3 trial, including post-treatment follow-up, as well as discussing the competitiveness of biosimilars.
Additionally, Celltrion will unveil, for the first time, the results of the global Phase 1 clinical trial of Cosentyx (active ingredient: secukinumab) biosimilar “CT-P55” via a poster presentation. The results will include a comparative study of pharmacokinetics, safety, and immunogenicity between CT-P55 and the original drug, conducted in healthy adult males.
Celltrion will also operate an exclusive promotional booth at the event, targeting local healthcare professionals attending EADV. The company plans to carry out a variety of marketing activities for its dermatology treatment portfolio, including Omliclo, which is scheduled for launch in Europe within this year, as well as Remsima SC, Yuflyma, and Stekima.
Developed by Celltrion, Omliclo is a biosimilar of Xolair, a widely used treatment for chronic spontaneous urticaria and asthma. Omliclo has secured “first-mover” status by becoming the first Xolair biosimilar to receive approval in major global markets such as Europe and the United States, and it is set to launch in Europe this year. The original drug, Xolair, recorded global sales of approximately 6.4992 trillion won as of last year.
Celltrion expects that, with the launch of Omliclo, it will further strengthen its competitiveness by expanding its product pipeline into new disease areas, following its already strong presence in the European market with autoimmune disease treatments and anticancer drugs.
A Celltrion representative stated, “At EADV, we plan to extensively showcase the research data for Omliclo, which is scheduled to launch in Europe this year as a first-mover, as well as the competitiveness of our entire dermatology treatment portfolio. Building on our successful establishment in the European market through the launch of autoimmune disease treatments and anticancer drugs, we will further solidify our market influence by expanding into new therapeutic areas.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
